Description

Zyceva 150 mg (Erlotinib Tablet) contains Erlotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is widely used in oncology for treating cancers driven by abnormal EGFR signaling.

🔬 Mechanism of Action

Erlotinib blocks the EGFR pathway, which plays a critical role in cancer cell growth, survival, and spread. By inhibiting EGFR, Zyceva 150 mg helps reduce tumor cell proliferation and may slow disease progression in eligible patients.

💊 Indications

Zyceva 150 mg is prescribed for:

• Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations
• Locally advanced or metastatic pancreatic cancer (in combination with gemcitabine)

📌 Key Features of Erlotinib Tablet

• Strength: 150 mg
• Dosage Form: Oral tablet
• Therapeutic Class: EGFR Tyrosine Kinase Inhibitor
• Administration: Taken once daily on an empty stomach (at least 1 hour before or 2 hours after food)
• Monitoring: Regular liver function tests and clinical evaluation recommended

⚕️ Benefits of Zyceva 150 mg

• Targeted therapy approach
• Oral administration for convenient dosing
• Helps improve progression-free survival in EGFR-positive patients

⚠️ Precautions

• Common side effects include rash, diarrhea, loss of appetite, and fatigue.
• Liver function and lung symptoms should be monitored during therapy.
• Dose adjustment may be required based on tolerance and response.
• Use only under oncologist supervision.

Zyceva 150 mg (Erlotinib Tablet) offers a precision-targeted treatment option for EGFR-driven cancers, supporting effective disease management with oral convenience and clinically established outcomes.